Replies to post #778106 on NorthWest Biotherapeutics Inc (NWBO)

[barnstormer]

Slave, I understand the need for caution, however at the last ASM Powers was able to discuss dealings with MHRA in general terms. Now, a year later the apparent concern is than any update, no matter how minor, will result in some sort of penalty or delay. Powers and Goldman are both attorneys and I would think they could find a way to present some update, even if minor and non-specific. As is, I'm left with an image of them being bound hand and foot, taped to a chair and gagged. Okay, that's probably a bit overboard, but after a year of any input from management except in required filings, maybe a metaphor is in order.
In a prior post, you compared shareholders frustration level and their need for patience with being at a window looking out. I would only add that at this point they would appreciate that window being opened just a crack to let in a little fresh air.

[AllSheWrote]

Narrator: "He was completely wrong."

[exwannabe]

So the new UK law allows Merck to manufacture (at least post Flaskworks) and sell DCVax-L in the US w/o FDA approval. This has got to be one of those alternate universe stories SF stories.

BTW, your stormwater discharge story is also from an alternate universe. Do you even know what it means?

[beartrap12]

Slave, I look forward to your response to my questions! I can wait. Meantime, keep your eyes on the road. Keep those kids safe!

[sukus]

Amazing insight. Thanks Slave. Keep them coming.

[Investor082]

LOL, no wonder LP diluted at .22 couple of weeks ago. The big pharma folks ran as fast and far away as possible after the TLD presentation in May 2022. No one is interested. It will be clear when ongoing dilution continues in pennies the rest of the year, in 2026, and beyond.

All time lows coming in September!

[Kam8]

👍👍👍💯💯💯

[Chiugray]

Andrew, Thanks for getting the message out there. I noticed your Winterfell post on X had 5,640 views after just 1 day. That’s noteworthy, as these types of posts are primarily viewed by investor and “to-be” folks. Another one of your posts on NWBO, posted a few months back had 1M views.

I have no inside information. I could be completely wrong. But what I am doing is connecting verifiable elements from infrastructure, regulatory history, engineering disclosures, and public records. The result is not speculation for hype. It is a strategic reading of what now appears to be one of the most deliberate immunotherapy deployment systems ever assembled in silence.

Those number of views speak to the quality of your dot-connecting. Whether it turns out to be fully the case, partially, or not, it provides me insight into how things work and their interconnectedness.

For sure, the asymmetric risk-reward investment opportunity in NWBO as a unicorn company is based on the ability to look forward. If what you see is true, or even partially, as with the implications of the Bosch Matrix, that alone is a catalyst of immense, hidden value.